An Open-label, Single-dose and Multiple-dose, Randomized, Crossover Study to Evaluate Pharmacokinetics, Safety and Tolerability After Administration of ALO-02 40 Mg Twice Daily Compared to ALO-02 80 Mg Once Daily and to Oxycontin 40 Mg Twice Daily in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2015
At a glance
- Drugs Oxycodone; Oxycodone/naltrexone
- Indications Pain
- Focus Pharmacokinetics
- 01 Sep 2015 Results published in the Clinical Pharmacology in Drug Development
- 03 May 2014 Results presented at the 33rd Annual Scientific Meeting of the American Pain Society.
- 27 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.